Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-15 EDT			5-day change	1st Jan Change
4,445.00 ^JPY	+1.93%		+1.18%	+6.31%

07-14	Sector Update: Health Care Stocks Decline Premarket Monday	MT
07-14	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Fresh Tariff Warnings	MT

Takeda Pharmaceutical Company Limited - Special Call

Published on 2025-06-01 at 21:05, updated on 2025-06-10 at 12:35

Presenter Speech
Elizabeth Borgeson (Executives)

Welcome to Takeda's ASCO IR event. We'll be discussing the rusfertide Phase III data today. This is Elizabeth from the IR team.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Takeda Pharmaceutical Company Limited

Sector Update: Health Care Stocks Decline Premarket Monday	07-14	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Fresh Tariff Warnings	07-14	MT
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (Tak-861) in Narcolepsy Type 1	07-14	CI
Takeda Pharmaceutical's Potential Narcolepsy Treatment Meets Endpoints in 2 Studies	07-14	MT
Takeda Pharmaceutical - positive results from two pivotal phase 3 studies of oveporexton (TAK-861) in narcolepsy type 1	07-14	RE
Takeda Completes Treasury Share Disposal Under Overseas Employee Incentive Plan	07-08	MT
US FDA approves KalVista's oral swelling disorder drug, shares rise	07-07	RE
Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	06-30	CI
Takeda Pharmaceutical Receives FDA Approval for Ready-to-Use Liquid Immunoglobulin Therapy	06-30	MT
Takeda Pharmaceuticals Gets FDA Approval for Liquid Gammagard	06-30	DJ
S&P Rates Takeda Pharmaceutical US Unit's Notes BBB+	06-27	MT
Takeda Pharmaceutical Company Limited, 2025 Earnings Call, May 08, 2025	06-26
Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025	06-25	CI
Takeda Pharmaceutical Company Limited - Special Call	06-10
Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting	06-09	MT
Trump's tariffs and threatened trade actions	06-04	RE
Trump's tariffs and threatened trade actions	06-04	RE
European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd	06-03	CI
Takeda Pharmaceutical Receives European Commission Approval for Adcetris Regimen to Treat Hodgkin Lymphoma	06-03	MT
Takeda to Withdraw, Replace Shelf Registration to Support Incentive Plan	06-03	MT
Takeda Pharmaceutical Says Co Will File Shelf Registration Statement In Japan	06-02	RE
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint	06-02	MT
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference	06-02	MT
Trump's tariffs and threatened trade actions	05-30	RE